Clinical trial
Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With…
NCT00386321 · Chulalongkorn University, Other · Terminated
Key facts
| NCT number | NCT00386321 |
|---|---|
| Title | Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma |
| Official title | Yt90Zevalin Plus CHOP, Z-CHOP |
| Lead sponsor | Chulalongkorn University, Other |
| Collaborators | Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Large B-cell Lymphoma |
| Intervention type | Drug |
| Interventions | Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin) |
| Enrollment | 10 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Oct 11, 2006 |
| Last update posted | Nov 18, 2010 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: